Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines June 7, 2022
XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT May 31, 2022
Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines May 31, 2022
Renovia advances access to first-line treatment for female urinary incontinence with 1,000 leva prescribers May 31, 2022
Lassen Therapeutics Presents Data Demonstrating Preclinical Anti-fibrotic Effect of LASN01, a Novel IL-11 Receptor-Blocking Antibody, at the American Thoracic Society 2022 Annual Meeting May 31, 2022
